Financial Toxicity Profiles and Associated Factors in Patients with Advanced Cancer Receiving Daytime Chemotherapy: A Latent Profile Analysis.

IF 2.6 4区医学 Q3 ONCOLOGY

Cancer Management and Research Pub Date : 2026-09-24 eCollection Date: 2026-01-01 DOI:10.2147/CMAR.S634242

Ying Zheng, Xiaoli Huang, Tao Xu, Jianqiong Feng, Qiu Wan, Xia Gan, Min Du

{"title":"Financial Toxicity Profiles and Associated Factors in Patients with Advanced Cancer Receiving Daytime Chemotherapy: A Latent Profile Analysis.","authors":"Ying Zheng, Xiaoli Huang, Tao Xu, Jianqiong Feng, Qiu Wan, Xia Gan, Min Du","doi":"10.2147/CMAR.S634242","DOIUrl":null,"url":null,"abstract":"Background: Financial toxicity (FT) may persist among patients with advanced cancer receiving daytime chemotherapy because of prolonged treatment, frequent hospital visits, and nonmedical expenses. However, heterogeneity in this outpatient setting remains insufficiently understood.Aim: To identify latent FT profiles among patients with advanced cancer receiving daytime chemotherapy and examine factors associated with profile membership.Methods: This cross-sectional study recruited 335 patients with advanced cancer receiving daytime chemotherapy in Southwest China from November 2025 to January 2026. Participants completed the COST-PROM scale, Hospital Anxiety and Depression Scale, and Family APGAR Index. Latent profile analysis identified FT profiles, and forced-entry multinomial logistic regression examined adjusted associations.Results: Three profiles were identified: High FT (32.5%, n=109), Moderate FT (31.7%, n=106), and Low FT (35.8%, n=120). Univariate comparisons showed significant differences across demographic, socioeconomic, clinical, and psychosocial characteristics. With High FT as the reference, a higher total HADS score, representing overall psychological distress, was associated with higher odds of Moderate FT membership (adjusted odds ratio (aOR) = 1.081, 95% CI: 1.042-1.121), whereas disease duration < 6 months versus > 1 year was associated with lower odds (aOR = 0.437, 95% CI: 0.203-0.937). For Low versus High FT membership, disease duration <6 months versus >1 year (aOR = 4.394, 95% CI: 1.749-11.041) and each one-point increase in Family APGAR score (aOR = 1.536, 95% CI: 1.235-1.910) were associated with higher adjusted odds.Conclusion: FT showed cross-sectional heterogeneity in this population. The observed associations may inform context-specific assessment and supportive-care planning, but profile selection and several regression estimates remain uncertain. External and longitudinal validation is required.","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"18 ","pages":"634242"},"PeriodicalIF":2.6000,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13618577/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S634242","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Financial toxicity (FT) may persist among patients with advanced cancer receiving daytime chemotherapy because of prolonged treatment, frequent hospital visits, and nonmedical expenses. However, heterogeneity in this outpatient setting remains insufficiently understood.

Aim: To identify latent FT profiles among patients with advanced cancer receiving daytime chemotherapy and examine factors associated with profile membership.

Methods: This cross-sectional study recruited 335 patients with advanced cancer receiving daytime chemotherapy in Southwest China from November 2025 to January 2026. Participants completed the COST-PROM scale, Hospital Anxiety and Depression Scale, and Family APGAR Index. Latent profile analysis identified FT profiles, and forced-entry multinomial logistic regression examined adjusted associations.

Results: Three profiles were identified: High FT (32.5%, n=109), Moderate FT (31.7%, n=106), and Low FT (35.8%, n=120). Univariate comparisons showed significant differences across demographic, socioeconomic, clinical, and psychosocial characteristics. With High FT as the reference, a higher total HADS score, representing overall psychological distress, was associated with higher odds of Moderate FT membership (adjusted odds ratio (aOR) = 1.081, 95% CI: 1.042-1.121), whereas disease duration < 6 months versus > 1 year was associated with lower odds (aOR = 0.437, 95% CI: 0.203-0.937). For Low versus High FT membership, disease duration <6 months versus >1 year (aOR = 4.394, 95% CI: 1.749-11.041) and each one-point increase in Family APGAR score (aOR = 1.536, 95% CI: 1.235-1.910) were associated with higher adjusted odds.

Conclusion: FT showed cross-sectional heterogeneity in this population. The observed associations may inform context-specific assessment and supportive-care planning, but profile selection and several regression estimates remain uncertain. External and longitudinal validation is required.

查看原文本刊更多论文

接受日间化疗的晚期癌症患者的财务毒性特征和相关因素：一项潜在特征分析。

背景：在接受日间化疗的晚期癌症患者中，由于治疗时间延长、频繁就诊和非医疗费用，财务毒性（FT）可能持续存在。然而，这种门诊设置的异质性仍然没有得到充分的了解。目的：确定接受日间化疗的晚期癌症患者的潜在FT谱，并检查与谱成员相关的因素。方法：本横断面研究于2025年11月至2026年1月在中国西南地区招募了335例接受日间化疗的晚期癌症患者。参与者完成成本- prom量表、医院焦虑抑郁量表和家庭APGAR指数。潜在特征分析确定了FT特征，强行进入多项逻辑回归检验了调整后的关联。结果：确定了三种特征：高FT (32.5%, n=109)，中度FT （31.7%, n=106）和低FT （35.8%, n=120）。单变量比较显示了人口统计学、社会经济、临床和社会心理特征的显著差异。以高FT为参照，较高的HADS总分（代表整体心理困扰）与较高的中度FT发生率相关（调整优势比(aOR) = 1.081, 95% CI: 1.042-1.121），而疾病持续时间< 6个月与bb10年相比，与较低的发生率相关（aOR = 0.437, 95% CI: 0.203-0.937）。对于低与高FT成员，疾病持续1年（aOR = 4.394, 95% CI: 1.749-11.041）和家庭APGAR评分每增加1分（aOR = 1.536, 95% CI: 1.235-1.910）与较高的调整后风险相关。结论：FT在该人群中表现出横断面异质性。观察到的关联可能为具体情况的评估和支持性护理计划提供信息，但概况选择和一些回归估计仍然不确定。需要外部和纵向验证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Management and Research Medicine-Oncology

CiteScore

7.40

自引率

0.00%

发文量

448

审稿时长

16 weeks

期刊介绍： Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.